DILIsym Services, a division of Simulations Plus

DILIsym Services, Inc. has developed DILIsym and NAFLDsym QSP software, and is developing IPFsymTM and RENAsymTM QSP software, to provide the pharmaceutical industry with the tools and resources to efficiently develop safe and effective drug therapies. DILIsym and RENAsym are designed to address drug-induced liver injury (DILI) and drug-induced acute kidney injury, respectively. NAFLDsym and IPFsym are designed for target or compound evaluation of therapeutic efficacy in nonalcoholic fatty liver disease (NAFLD or NASH) and idiopathic pulmonary fibrosis (IPF), respectively. Thus, DILIsym and RENAsym may be applied to address drug safety across therapeutic areas, while NAFLDsym and IPFsym may be...

Software,consulting services,drug-induced liver injury,modeling & simulation,non-alchoholic fatty liver disease,metabolic diseases,non-alcoholic steatohepatitis,nafld,nash,biotechnology,pharmaceuticals,mathematical modeling,quantitative systems pharmacology,quantitative systems toxicology,drug-induced kidney injury,consortium,acute kidney injury,idiopathic pulmonary fibrosis,simulated populations sim-pops™,mitochondrial dysfunction,and hepatocytes

Dilisym services, a division of simulations plus operates in the Biotechnology research industry.

Dilisym services, a division of simulations plus's revenue is 11m - 100m

Dilisym services, a division of simulations plus has 11 - 50 employees.